ARS Pharmaceuticals director granted 30,000 stock options

ARS Pharmaceuticals director Phillip M. Schneider received a grant of stock options as compensation.

Rhea-AI Filing Summary

ARS Pharmaceuticals director Phillip M. Schneider received a grant of stock options as compensation. On June 24, 2026, he was awarded options covering 30,000 shares of common stock with an exercise price of $10.54 per share. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting and expire on June 23, 2036. After this grant, Schneider holds 30,000 stock options directly, and the transaction does not involve any open-market buying or selling of shares.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider SCHNEIDER PHILLIP M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Key Figures

Stock options granted: 30,000 options Exercise price: $10.54 per share Underlying shares: 30,000 shares +3 more

6 metrics

Stock options granted 30,000 options Grant to director on June 24, 2026

Exercise price $10.54 per share Strike price of stock option grant

Underlying shares 30,000 shares Common stock underlying the options

Post-grant option holdings 30,000 options Total derivative position following transaction

Vesting date Earlier of June 24, 2027 or 2027 annual meeting Vesting condition for entire option grant

Expiration date June 23, 2036 Option term end date

Key Terms

Stock Option (right to buy), exercise price, vest in full, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "10.5400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares subject to the option will vest in full on the earlier of June 24, 2027..."

expiration date financial

"expiration_date: "2036-06-23T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARS Pharmaceuticals (SPRY) director Phillip M. Schneider report in this Form 4?

Phillip M. Schneider reported receiving a grant of stock options for 30,000 shares of ARS Pharmaceuticals common stock. The options were awarded as compensation, not purchased on the open market, and give him the right to buy shares at a fixed exercise price.

How many ARS Pharmaceuticals (SPRY) shares are covered by Schneider’s new stock options?

The grant covers 30,000 shares of ARS Pharmaceuticals common stock. These are options, meaning they provide the right to buy shares in the future, rather than current ownership of the underlying common stock itself.

What is the exercise price of Phillip M. Schneider’s ARS Pharmaceuticals (SPRY) stock options?

The options have an exercise price of $10.54 per share. This is the price at which Schneider can purchase ARS Pharmaceuticals common stock if he exercises the options during their term before expiration.

When do Phillip M. Schneider’s ARS Pharmaceuticals (SPRY) stock options vest?

The options vest in full on the earlier of June 24, 2027 or the date of ARS Pharmaceuticals’ 2027 annual stockholder meeting. The exact meeting date has not yet been set by the company’s board of directors.

What is the expiration date of Schneider’s ARS Pharmaceuticals (SPRY) stock options?

These stock options expire on June 23, 2036. If Schneider does not exercise the options by that date, his right to buy the 30,000 underlying ARS Pharmaceuticals common shares at $10.54 per share will lapse.

Did Phillip M. Schneider buy or sell ARS Pharmaceuticals (SPRY) shares in the market?

No, this Form 4 reports a stock option grant, not a market trade. Schneider acquired derivative securities as compensation, and there were no open-market purchases or sales of ARS Pharmaceuticals common stock in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHNEIDER PHILLIP M

(Last) (First) (Middle)

C/O ARS PHARMACEUTICALS, INC.

11682 EL CAMINO REAL, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARS Pharmaceuticals, Inc. [ SPRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.54	06/24/2026		A		30,000		(1)	06/23/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

	/s/ Kathleen Scott, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)